Biolegend, 124307, PE anti-mouse CD274 (B7-H1, PD-L1) Antibody, 25μg

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Formulation: Phosphate buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Maier H, et al. 2007. J. Immunol. 178:2714. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC) Paterson AM, et al. 2011. J. Immunol. 187:1097. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block) Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed Murakami R, et al. 2013. PLoS One. 8:73270. PubMed Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC) Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations: Pi C, et al. 2022. Cancers (Basel). 14:. PubMed Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed Ou W, et al. 2023. Nat Commun. 14:392. PubMed Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed Yi J, et al. 2023. Nat Commun. 14:1941. PubMed Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed Liu J, et al. 2023. Nat Commun. 14:2806. PubMed Liu Z, et al. 2023. Front Pharmacol. 14:1154392. PubMed Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed Xin B, et al. 2022. Hepatology. 76:630. PubMed Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed Shi J, et al. 2018. Immunity. 49:264. PubMed Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed Lu SX, et al. 2021. Cell. . PubMed Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed Li H, et al. 2021. Nat Commun. 12:2773. PubMed Dichtl S, et al. 2021. Sci Adv. 7: . PubMed Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed Wang B, et al. 2022. Nat Commun. 13:3821. PubMed Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed Wu L, et al. 2022. Theranostics. 12:842. PubMed Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed Takano T, et al. 2020. Front Immunol. 11:1555. PubMed Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed Webb ER, et al. 2022. iScience. 25:104995. PubMed Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed Moon S, et al. 2021. J Exp Med. 218:. PubMed Huang J, et al. 2014. J Immunol. 192:1972. PubMed Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed Yin X, et al. 2020. Cell Rep. 33:108278. PubMed Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed Haile S, et al. 2011. J Immunol. 186:6822. PubMed Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed Zheng Y, et al. 2022. Transl Res. :. PubMed Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed Qi S, et al. 2020. Theranostics. 10:1814. PubMed Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed Wang H, et al. 2022. J Cancer. 13:2126. PubMed Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
RRID: AB_2073557 (BioLegend Cat. No. 124307) AB_2073556 (BioLegend Cat. No. 124308)
Structure: 40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution: T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes
Ligand/Receptor: PD-1 (PDCD1)
Cell Type: B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area: Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family: Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Sharpe A, et al. 2007. Nat. Immunol. 8:239. 2. Dong H, et al. 1999. Nat. Med. 5:1365. 3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.
Gene ID: 60533
UniProt: View information about CD274 on UniProt.org
Clone: 10F.9G2
Regulatory Status: RUO
Other Names: B7-H1, PD-L1
Isotype: Rat IgG2b, κ
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.